Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The BREAKER-101 Study
NCT06625775Phase 1Recruiting
- Sponsor
- TheRas, Inc.
- Start
- Oct 2024
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of bbo-10203 in breast cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 1 more (5 arms), sponsored by TheRas, Inc. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase 2 Dose, Adverse Events and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
bbo-10203
03
Conditions
breast cancercolorectal cancer (CRC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT06625775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625775.